Once-yearly local therapy for EoE: Long-acting, injectable fluticasone in development for treating eosinophilic esophagitis (EoE)
EP-104GI is an investigational, long-acting, injectable fluticasone propionate formulation developed by Eupraxia Pharmaceuticals for treating Eosinophilic Esophagitis (EoE). It is designed to be injected into the esophageal wall to provide localized, sustained release of medication over several months.
Eupraxia Pharmaceuticals delivered exciting interim results from its ongoing RESOLVE trial, offering fresh hope for people with eosinophilic esophagitis (EoE), a chronic allergic condition that causes inflammation and scarring in the esophagus.
EP-104GI is a locally injected therapy using Eupraxia's proprietary Diffusphere™ technology for controlled, long-lasting release of medication directly in the affected tissue.
In the highest-dose cohort (8 mg per site across 20 injection sites), patients achieved improvements by week 12:
EoEHSS Grade score improved by 94%
EoEHSS Stage score improved by 97%
These changes reflect near-complete normalization of tissue health on biopsy.
Longer-term data were also encouraging. Patients in the 4 mg/site dose groups maintained meaningful tissue improvements at 36 weeks. Across broader groups with substantial esophageal coverage, clinical remission (significant symptom relief) reached 58% at 12 weeks, 79% at 24 weeks, and 67% at 52 weeks.
These early findings highlight the potential of targeted, once-yearly local therapy to address the root pathology of EoE more effectively than current options.
Eosinophilic Esophagitis: Management in 4 steps (click here to enlarge the image).
References: